Results 231 to 240 of about 26,548 (293)

Monitoring renal safety in mineralocorticoid receptor antagonist trials [PDF]

European Journal of Heart Failure, 2017
openaire   +2 more sources

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

British Journal of Pharmacology, Volume 183, Issue 7, Page 1502-1516, April 2026.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy, Tamás Radovits, Tímea Bálint, Zoltán Horváth, Petra Kocsis‐Balogh, Ákos Gergely Tóth, Attila Oláh, Alex Ali Sayour, Bálint András Barta, Béla Merkely, Mihály Ruppert   +10 more
wiley   +1 more source

Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial. [PDF]

Kidney Dis (Basel)
Cherney DZI, Frederich R, Pratley RE, Cosentino F, Dagogo-Jack S, Pong A, Gantz I, Cater NB, Mancuso JP, Masiukiewicz U, Cannon CP.   +10 more
europepmc   +1 more source

Diabetic kidney disease, biomarkers, and finerenone

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2582-2593, April 2026.
Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Ashish Verma, Ashish Upadhyay
wiley   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3126-3136, April 2026.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

A Randomized trial assessing Efficacy and safety of Mineralocorticoid receptor Antagonist therapy compared to Standard antihypertensive Therapy in hypErtension with low Renin (REMASTER): rationale and study design. [PDF]

J Hum Hypertens
Shah SS, Gwini SM, Stowasser M, Reid CM, Young MJ, Fuller PJ, Yang J.   +6 more
europepmc   +1 more source

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3137-3145, April 2026.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen, Yu‐Wen Tseng, Chi‐Jung Huang, Shu‐Mei Yang, Marat Fudim, Shao‐Yuan Chuang, Shih‐Hsien Sung, Hao‐Min Cheng   +7 more
wiley   +1 more source

Associations of 24‐Hour Urinary Sodium, Potassium Excretion and Sodium‐to‐Potassium Ratio With Longitudinal Home Blood Pressure Control in Patients With Apparent Treatment‐Resistant Hypertension

The Journal of Clinical Hypertension, Volume 28, Issue 4, April 2026.
ABSTRACT Dietary sodium and potassium intake are key determinants of blood pressure (BP) control in hypertensive patients. However, their associations with longitudinal home BP control in patients with apparent treatment‐resistant hypertension (aTRH) remain unclear.
Weikang Bian, Fanglu Wang, Hao Wang, Qiaoyu Shao, Shicheng Li, Shuyang Zhang, Xiaowei Yan   +6 more
wiley   +1 more source

Mechanisms of hesperetin in alleviating diabetic nephropathy: Network pharmacology, molecular docking, and experimental validation

Journal of Diabetes Investigation, Volume 17, Issue 4, Page 576-587, April 2026.
Hesperetin increases cell viability and reduces cell apoptosis, ferroptosis, release of inflammatory cytokines, and oxidative stress of human kidney tubular cells via repressing IGF1R expression. ABSTRACT Background Diabetic nephropathy (DN) accounts for approximately 50% of chronic kidney disease cases.
Yiwen Guo, Fengjiao Zhang, Yu Jin, Menglu Zhu, Zhiqiang Kang   +4 more
wiley   +1 more source

Optimizing the diagnosis of primary aldosteronism: The role of adrenal vein sampling and the need for high‐expertise reference centers

Journal of Neuroendocrinology, Volume 38, Issue 4, April 2026.
Abstract Adrenal vein sampling (AVS) is the cornerstone diagnostic procedure for subtype differentiation in primary hyperaldosteronism, guiding therapeutic decision‐making and offering the possibility of curative surgery to a subset of patients.
Aura D. Herrera‐Martínez, Ángel Rebollo‐Román, Pablo Remón‐Ruiz, María José Picón‐César, Patricia Guirado‐Peláez, Carmen Tenorio‐Jiménez, Carlos López‐Pereira, Manuel Aguilar‐Diosdado, Marta Iturregui‐Guevara, Viyey K. Doulatram‐Gamgaram, Maria Eugenia Pérez‐Montilla, Juan José Espejo‐Herrero, Ma Ángeles Galvez‐Moreno, Alfonso Soto‐Moreno, on behalf of the Neuroendocrine Group of the Andalusian Society of Endocrinology, Diabetes and Nutrition   +15 more
wiley   +1 more source